Antihyperglycemic medication use was assessed on the drug class level including metformin, sulfonylureas, thiazolidinediones, SGLT2i
When Trulicity is added to existing metformin and/or pioglitazone therapy, the current dose of metformin and/or pioglitazone can be continued. SGLT2i When Trulicity is added to existing metformin and/or sodium-glucose co-transporter 2 inhibitor (SGLT2i) therapy, the current dose of metformin and/or SGLT2i can be continued.
In general, the distribution of each indicator was similar in SGLT2i-related AEs and IMEs. For SGLT2i-related IMEs, monotherapy (94.99%) accounted for a much larger proportion than combination therapy, with canagliflozin constituting nearly half (48.26%). The vast majority of reports cited SGLT2i as the primary suspect drug (94.55%).
Recommendation for addition of an SGLT2i (or GLP-1RA where SGLT2i is not tolerated or contraindicated) to other glucose lowering medication(s) in adults
If a patient is already on metformin and/or sodium-glucose co-transporter 2 inhibitor (SGLT2i) therapy, the current dose of metformin and/or SGLT2i can be
Dulaglutide / Trulicity (GLP1-RA); Empagliflozin / Jardiance (SGLT2i); Liraglutide / Victoza (GLP1-RA) Empagliflozin / Jardiance (SGLT2i); Sitagliptin
Sodium/glucose cotransporter-2 inhibitors (SGLT2i) are a new type of glucose-lowering drug that can reduce blood glucose by inhibiting its reabsorption in proximal tubules and by promoting urinary glucose excretion. SGLT2i are widely used in the clinical treatment of type 2 diabetes mellitus (T2DM). In recent studies, SGLT2i were found to not only reduce blood glucose but also protect the
When Trulicity is added to existing metformin and/or pioglitazone therapy, the current dose of metformin and/or pioglitazone can be continued. SGLT2i When Trulicity is added to existing metformin and/or sodium-glucose co-transporter 2 inhibitor (SGLT2i) therapy, the current dose of metformin and/or SGLT2i can be continued.
Recommendation for addition of an SGLT2i (or GLP-1RA where SGLT2i is not tolerated or contraindicated) to other glucose lowering medication(s) in adults
Comments